Avertix Medical—formerly known as Angel Medical Systems—has announced that Ian Meredith has agreed to join the company’s board of directors.
Avertix is commercialising a US Food and Drug Administration (FDA)-approved heart attack warning system to improve long-term management and outcomes of high-risk coronary disease in patients
Meredith’s appointment was announced following the closing of the company’s business combination with BIOS Acquisition Corporation, a special purpose acquisition company.
Meredith recently retired from Boston Scientific after serving over six years as its executive vice president and global chief medical officer, where he was responsible for global leadership of medical, clinical science and trial strategy across the organisation. Prior to joining Boston Scientific, Meredith served for 12 years as a professor and director of MonashHeart and today serves as an honorary professor of medicine and cardiology at Monash University in Melbourne, Australia.
As an Avertix board member, Meredith will bring his decades long experience as a leading interventional cardiologist and thought leadership to the company, a press release states.
“We believe Professor Meredith is one of the world’s most eminent clinicians in both acute cardiac care and clinical investigations,” said Ross Haghighat, executive chairman of Avertix. “As a highly respected and globally recognised interventional cardiologist, professor, and global medical executive of one of the most innovative cardiovascular product companies in the world, we believe his expertise and insights will prove invaluable to Avertix. We are thrilled to have his guidance extend beyond the boardroom as we endeavour to advance both The Guardian System and our pipeline of future innovations which we expect to shape a new era of cardiac monitoring for patients worldwide.”
“Avertix has a meaningful product that holds the potential to empower patients at a time of great anxiety and uncertainty in their lives,” said Meredith. “I can say confidently after 35 years of caring for patients suffering a heart attack, with more than 20 of those as an interventional cardiologist undertaking primary percutaneous coronary intervention (PCI) for their acute heart attack, that the fear of another cardiac event, and resulting death, is profound and often paralysing to the point that many struggle to return to their normal daily activities, both personally and professionally. I believe the aptly named Guardian offers a promising solution, providing individuals with renewed confidence and a sense of predictability—albeit not absolute.”
